The most common and popular technique of cell therapy aims at using healthy cells from a compatible donor (Allogeneic) or from the patient itself (Autogenic) and their modification to amplify their therapeutic ability. The complex steps that are involved in it are the genetic screening of the cell, modification of a cell by genetic sequencing, their harvesting, and reinfusion into the patient's body. Each of these steps plays a key role in therapeutic development, this leads to the establishment of the global cell-based therapy market. Several indications have found to be curable with the help of cell therapies, and these indications are expected to increase in the near future. Cerebral disorders including Parkinson’s disease and Alzheimer’s disease are under investigation to treat with the help of cell therapies. They are also investigated for cardiovascular disease in which the aim is to restore normal heart functions.
The Global Cell Therapy Market size was valued at USD xx billion in 2018, and It is likely to grow at 13.1% CAGR during the forecast period. The increasing prevalence of chronic diseases and lifestyle disorders like cancer, cardiovascular, diabetes, arthritis, and epilepsy, is one of the major factors for the growth of the cell-based therapy market. The cell-based assays for the nervous system and chronic pain provide new opportunities for developing novel medicines for pain and neurodegenerative diseases. Cell-based assays are useful highly in screening mutagenesis in various types of cancers, such as chronic myeloid leukemia.
The rise in chronic diseases, in turn, raise the demand for cell-based assays for new drug discoveries, making it a key factor for the growth of the global market. Other factors playing a vital role for the growth of this market include increasing investments in R&D for drug discovery, technological advancements in cell-based methodologies, and rising adoption of high-throughput screening methods, particularly in toxicological studies. In addition, declining prices of stem cell therapies are leading to the increased inclination of buyers towards cell therapy.
The approval of first Cell Therapy, Carticel®, in 1997 in the US, has rapidly advanced and currently, a number of similar therapies are under development. The examples of approved cell-based therapies include CreaVax-RCC®, JACE, Carticel®, ReliNethra, Prochymal®, and Provenge®. As the majority of cell-based therapy products are in the early phase of development, several numbers of manufacturers are going to meet the clinical scale production requirements. In Feb. 2019, The US FDA and the Data and Safety Monitoring Board (DSMB) grants permission to resume enrolment of CAP 1002 in the phase II HOPE-2 study for Duchenne muscular dystrophy. U.S. Food and Drug Administration (FDA) expects more than 200 investigational new drug applications (IND) by 2020 per year, many of the cell and gene therapies, the agency issued an outline of new procedures it plans to implement this year.
The Global Cell Therapy market is segmented on the basis of type, technology, cell source, application, and end-user.
Based on Type: autologous and allogeneic.
Based on Technology: Cell immortalization technology, somatic cell technology, genome editing technology, cell plasticity technology, viral vector technology, and three-dimensional technology. The viral vector technology is further segmented into Ex vivo gene modification of cells and In vivo gene modification of cells.
Based on Cell source: Induced pluripotent stem cells (iPSCs), bone marrow, umbilical cord blood-derived cells, adipose tissue, and neural stem cell.
Based on Application: Musculoskeletal, cardiovascular, gastrointestinal, neurological, oncology, dermatology, wounds and injuries, ocular, and others.
Based on End-users: Hospital & clinics, diagnostic centers, regenerative medicine centers, research institutes, and others.
Based on Geographically: the Americas dominate the cell therapy market owing to high healthcare expenditure and the rise in awareness among people. Europe stands for the second position in the cell-based therapy market. It is anticipated that the support provided by government bodies for R&D and increase in reimbursement policies in healthcare is going to drive the market in the Europe region. The Asia Pacific is known to be the fastest-growing cell therapy market leading to a huge patient pool, developing healthcare technology and improving healthcare expenditure. The Middle East & Africa is found to have the lowest market for cell-based therapy because of the lack of technical knowledge and poor medical facilities.
Some of the key players in the Cell Therapy Market are Novartis AG, GlaxoSmithKline plc, Osiris, PHARMICELL, NuVasive, Inc., ANTEROGEN.CO. Ltd., Cynata, CELLECTIS, BioNTech IMFS, EUFETS GmbH, JCR Pharmaceuticals Co., Ltd, Cognate, Pluristem, Grupo Praxis, Genzyme Corporation, Advanced Tissue, and others.
The report covers in-depth analysis of the Global Cell Therapy Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (cardiovascular, gastrointestinal, neurological, oncology, dermatology, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Cell Therapy Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.